• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

Introduction to [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride (CAS No. 1609403-88-4)

[1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride (CAS No. 1609403-88-4) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as Isoxazolylmethylamine hydrochloride, is a derivative of pyrazole and exhibits a unique combination of structural features that make it an attractive candidate for various applications, particularly in drug discovery and development.

The chemical structure of [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride consists of a pyrazole ring attached to a methylamine group, with an isopropyl substituent on the pyrazole ring. The presence of the hydrochloride salt form ensures good solubility in aqueous solutions, which is crucial for its use in biological assays and pharmaceutical formulations.

Recent studies have highlighted the potential of [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride as a lead compound for the development of novel therapeutic agents. One notable area of research is its activity as a modulator of G protein-coupled receptors (GPCRs). GPCRs are a large family of membrane receptors that play critical roles in various physiological processes, including neurotransmission, immune responses, and hormone signaling. The ability of [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride to interact with specific GPCRs has been explored in several preclinical studies, demonstrating its potential as a ligand for these receptors.

In addition to its GPCR modulating properties, [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride has shown promise in the treatment of neurological disorders. Preclinical studies have indicated that this compound can cross the blood-brain barrier and exert neuroprotective effects. These findings suggest that it may be useful in the development of drugs for conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The pharmacokinetic properties of [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride have also been extensively studied. Research has shown that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles, making it suitable for oral administration. This is particularly important for drug development, as compounds with good oral bioavailability are often preferred due to their ease of use and patient compliance.

Clinical trials are currently underway to evaluate the safety and efficacy of [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride in human subjects. Early results from phase I trials have been promising, with no significant adverse effects reported at therapeutic doses. These findings provide a strong foundation for further clinical development and potential commercialization.

Beyond its therapeutic applications, [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride has also found use in chemical synthesis and as a building block for the preparation of more complex molecules. Its unique structural features make it an excellent starting material for the synthesis of derivatives with enhanced biological activities or improved pharmacological properties.

In conclusion, [1-(propan-2-yl)-1H-pyrazol-4-yl]methanamine hydrochloride (CAS No. 1609403-88-4) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure, favorable pharmacokinetic properties, and promising preclinical results make it an attractive candidate for further investigation and development. As research in this area continues to advance, it is likely that new insights into the therapeutic potential of this compound will emerge, potentially leading to the development of novel treatments for various diseases and conditions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)